Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OVV 01

Next Previous
Drug Profile

OVV 01

Alternative Names: C 045; OVV-01

Latest Information Update: 23 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Joint Biosciences
  • Developer Beijing Boren Hospital; Joint Biosciences
  • Class Antineoplastics; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Lymphoma; Solid tumours

Most Recent Events

  • 23 Jun 2026 Phase-I development is ongoing China
  • 16 Jun 2026 Chinese Academy of Medical Sciences plans a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Monotherapy, Combination therapy) in China (IV, Intratumoural) in August 2026 (NCT07650825)
  • 16 Jun 2026 Joint Biosciences in collaboration with Cancer Institute and Hospital plans a phase II trial for Soft tissue sarcoma (Late-stage disease, Second-line therapy or greater, Metastatic disease, Inoperable/Unresectable, Recurrent) in August 2026 (Parentral) (NCT07650838)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top